MedPath

A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Phase 2
Completed
Conditions
Cervical Cancer
Interventions
Registration Number
NCT04300647
Lead Sponsor
Hoffmann-La Roche
Brief Summary

The purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in patients with programmed death-ligand 1 (PD-L1)-positive cervical cancer (metastatic and/or recurrent).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
172
Inclusion Criteria
  • Histologically confirmed recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix after progression on or after 1-2 lines of prior systemic chemotherapy in the metastatic/recurrent setting that is not amenable to curative treatment with systemic chemotherapy, surgery, and/or radiotherapy
  • Radiologically-measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1
  • Cervical cancer tissue for study analysis (archival or fresh biopsy specimen)
  • Life expectancy of at least 12 weeks
  • Adequate hematologic and organ function
  • Female of childbearing potential must be willing to comply with adequate contraception
Exclusion Criteria
  • Treatment with investigational therapy with therapeutic intent within 28 days prior to randomization
  • Active or untreated central nervous system (CNS) or brain metastases
  • Active or history of autoimmune disease or immune deficiency
  • Active tuberculosis
  • Known, clinically significant liver disease
  • Severe infection per investigator judgement at the time of randomization or any active infection that, in the opinion of the investigator, could impact patient safety
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to randomization
  • Treatment with systemic immunosuppressive medications within 1 week prior to randomization or anticipation of need for systemic immunosuppressive medication during study
  • Pregnant or breastfeeding woman
  • Known hypersensitivity to any component of the tiragolumab or atezolizumab formulations

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AtezolizumabAtezolizumabParticipants will receive atezolizumab monotherapy until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Tiragolumab plus AtezolizumabTiragolumabParticipants will receive tiragolumab and atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Tiragolumab plus AtezolizumabAtezolizumabParticipants will receive tiragolumab and atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Primary Outcome Measures
NameTimeMethod
Independent Review Committee (IRC)-Assessed Objective Response Rate (ORR)From randomization up to approximately 17 months

ORR is defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions \>/=4 weeks apart, as determined by the IRC according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. The study enrolled patients with measurable disease as determined by the investigator. Participants found to have non-measurable disease at baseline according to RECIST v1.1 (through IRC assessment or Protocol Deviations) were only considered responders if they achieved a CR.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With Adverse EventsUp to 36 months

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

IRC-Assessed Duration of Response (DOR)First occurrence of a documented objective response to the date of disease progression or death from any cause, whichever occurs first (up to approximately 17 months)

DOR is defined for participants who had an objective response as the time from the first occurrence of a documented objective response (CR or PR) to the date of progressive disease (PD) or death from any cause (whichever occurred first), as determined by the IRC according to RECIST v1.1. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline). The study enrolled patients with measurable disease as determined by the investigator. Participants found to have non-measurable disease at baseline according to RECIST v1.1 (through IRC assessment or Protocol Deviations) were only considered responders if they achieved a CR.

IRC-Assessed Disease Control Rate (DCR)From randomization up to approximately 17 months

Disease control rate is defined as the percentage of participants with a CR, PR, or stable disease (SD), as determined by the IRC according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD: neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. Participants were classified as SD only if SD was observed on two consecutive assessments \>/= 6 weeks apart. The study enrolled patients with measurable disease as determined by the investigator. Participants found to have non-measurable disease at baseline according to RECIST v1.1 (through IRC assessment or Protocol Deviations) were only considered responders if they achieved a CR.

Investigator-Assessed Best Clinical Response (BCR) RateFrom randomization up to approximately 17 months

BCR is defined as the percentage of participants with a CR, PR, or SD, as determined by the investigator. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD: neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. Participants were classified as SD only if SD was observed on two consecutive assessments \>/= 6 weeks apart.

Investigator-Assessed Duration of BCRFirst occurrence of a documented clinical response to the date of disease progression or death from any cause, whichever occurs first (up to approximately 17 months)

Duration of BCR is defined for BCR responders as the time from the first occurrence of a documented response (CR, PR, or SD) to the date of PD or death from any cause (whichever occurred first), as clinically determined by the investigator according to RECIST v1.1. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD: neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. Participants were classified as SD only if SD was observed on two consecutive assessments \>/= 6 weeks apart. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline).

IRC-Assessed Progression-Free Survival (PFS)From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 17 months)

PFS is defined as the time from randomization to the first occurrence of PD or death from any cause (whichever occurred first), as determined by the IRC according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline).

IRC-Assessed PFS Rate at 6 Months6 months

PFS rate is defined as the percentage of participants that were event free, as determined by the IRC according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline).

Overall Survival (OS)From randomization to death from any cause (up to approximately 17 months)

OS is defined as the time of randomization to death from any cause.

OS Rate at 6 Months and 12 Months6 months, 12 months

Reported here are the percentages of participants who were still alive at 6 months and 12 months.

Trial Locations

Locations (56)

Policlinico Universitario Agostino Gemelli

🇮🇹

Roma, Lazio, Italy

Centro Oncológico de Panamá

🇵🇦

Panama, Panama

The Panama Clinic

🇵🇦

Panama, Panama

Clinica Ricardo Palma

🇵🇪

San Isidro, Peru

Szpital Morski im.PCK

🇵🇱

Gdynia, Poland

Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice

🇵🇱

Gliwice, Poland

Wielkopolskie Centrum Onkologii im. M. Sklodowskiej-Curie

🇵🇱

Poznan, Poland

Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie

🇵🇱

Warszawa, Poland

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Maharaj Nakorn Chiang Mai Hospital

🇹🇭

Muang, Thailand

University College London Hospital

🇬🇧

London, United Kingdom

Sarah Cannon Research Institute

🇬🇧

London, United Kingdom

Oncology Associates of Oregon, P.C

🇺🇸

Eugene, Oregon, United States

Clinica CIMCA

🇨🇷

San José, Costa Rica

ICIMED Instituto de Investigación en Ciencias Médicas

🇨🇷

San José, Costa Rica

Centre Leon Berard

🇫🇷

Lyon, France

Institut Paoli Calmettes

🇫🇷

Marseille, France

Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque

🇫🇷

Montpellier, France

ICO - Site René Gauducheau

🇫🇷

Saint Herblain, France

Gustave Roussy

🇫🇷

Villejuif CEDEX, France

Istituto Tumori Napoli

🇮🇹

Napoli, Campania, Italy

Arizona Oncology Associates

🇺🇸

Phoenix, Arizona, United States

Kaiser Permanente - Irvine

🇺🇸

Irvine, California, United States

Augusta University

🇺🇸

Augusta, Georgia, United States

MEDSI Clinical Hospital on Pyatnitsky Highway

🇷🇺

Moscow, Moskovskaja Oblast, Russian Federation

Mater Misericordiae Limited

🇦🇺

South Brisbane, Queensland, Australia

Hospital Sao Rafael - HSR

🇧🇷

Salvador, Bahia, Brazil

Hospital Araujo Jorge

🇧🇷

Goiania, Goiás, Brazil

Hospital de Caridade de Ijui

🇧🇷

Ijui, Rio Grande Do Sul, Brazil

Hospital Nossa Senhora da Conceicao

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

🇧🇷

Sao Paulo, São Paulo, Brazil

Royal Victoria Regional Health Centre

🇨🇦

Barrie, Ontario, Canada

London Regional Cancer Centre

🇨🇦

London, Ontario, Canada

Princess Margaret Cancer Center

🇨🇦

Toronto, Ontario, Canada

Jewish General Hospital

🇨🇦

Montreal, Quebec, Canada

McGill University Health Centre - Glen Site

🇨🇦

Montreal, Quebec, Canada

Istituto Europeo Di Oncologia

🇮🇹

Milano, Lombardia, Italy

Keimyung University Dongsan Hospital

🇰🇷

Daegu, Korea, Republic of

Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Christus Muguerza Clinica Vidriera

🇲🇽

Monterrey, Nuevo LEON, Mexico

Chelyabisnk regional clinical center for oncology and nuclear medicine

🇷🇺

Chelyabinsk, Sverdlovsk, Russian Federation

Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic

🇷🇺

Kazan, Tatarstan, Russian Federation

Tomsk scientific research institute of oncology SO RAMN, PAD

🇷🇺

Tomsk, Russian Federation

Volgograd Regional Clinical Oncology Dispensary

🇷🇺

Volgograd, Russian Federation

Complejo Hospitalario Universitario A Coruña (CHUAC)

🇪🇸

La Coruna, Spain

Taichung Veterans General Hospital

🇨🇳

Taichung, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei City, Taiwan

Taipei Veterans General Hospital

🇨🇳

Taipei City, Taiwan

Mackay Memorial Hospital

🇨🇳

Taipei City, Taiwan

Chang Gung Medical Foundation, Linkou Branch

🇨🇳

Taoyuan City, Taiwan

© Copyright 2025. All Rights Reserved by MedPath